Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cellular Biomedicine Group, Inc. (NASDAQ: CBMG).

Full DD Report for CBMG

You must become a subscriber to view this report.


Recent News from (NASDAQ: CBMG)

Cellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational Progress
China Food and Drug Administration Accepts the Company’s Investigational New Drug (IND) Applications for anti-CD19 CAR-T Therapy Targeting NHL and ALL Positive 48-Week Phase I Clinical Data of AlloJoin TM  haMPC therapy for KOA in China Ended quarter with $45.6 milli...
Source: GlobeNewswire
Date: May, 08 2018 06:00
Cellular Biomedicine Group Announces Results of 2018 Annual Meeting of Stockholders
SHANGHAI, China and CUPERTINO, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc . (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cel...
Source: GlobeNewswire
Date: April, 30 2018 08:30
Week In Review: James Watson To Lead New Shenzhen Biopharma Research Center
Industry Developments James Watson, who co-discovered the double-helix structure of DNA in 1953, will lead a new international life science research center in the International Bio Valley, located in Shenzhen's Dapeng New Area. A groundbreaking ceremony was held last Friday with Dr. Watson i...
Source: SeekingAlpha
Date: March, 25 2018 09:31
Wired News - Cellular Biomedicine's 48-Week Data off China-based Phase-I Clinical Trial Shows Positive Result for AlloJoin(TM) for Treatment of KOA
Stock Monitor: AnaptysBio Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Cellular Biomedicine Group Inc. (NASDAQ: CBMG ) ("CBMG"). If you want access to this report all you need to do is sign up now ...
Source: ACCESSWIRE IA
Date: March, 20 2018 07:40
Cellular Bio pivots to China on development of AlloJoin for knee osteoarthritis
Buoyed by encouraging 48-week data from a China-based Phase 1 clinical trial assessing AlloJoin in patients with knee osteoarthritis (KOA), Cellular Biomedicine Group (NASDAQ: CBMG ) will shelve its U.S. activities to focus on what it believes is a faster and more cost-effective route to a...
Source: SeekingAlpha
Date: March, 16 2018 07:36
Cellular Biomedicine Group Announces Positive 48-Week Clinical Data of AlloJoin(TM) Human Adipose-Derived Mesenchymal Progenitor Cell (haMPC) Knee Osteoarthritis (KOA) China Phase I Trial
SHANGHAI, China and CUPERTINO, Calif., March 16, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell ...
Source: GlobeNewswire
Date: March, 16 2018 07:00
Cellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data from Phase I Clinical Trial for AlloJoin(TM) Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis
SHANGHAI, China and CUPERTINO, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell thera...
Source: GlobeNewswire
Date: March, 14 2018 07:30
Premarket analyst action - healthcare
Cowen, Barclays and ROTH all host healthcare conferences next week. More news on: Anavex Life Sciences Corp., Owens & Minor Inc., Verastem, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: March, 08 2018 08:26
Cellular Biomedicine Group Reports Full-Year 2017 Financial Results and Recent Operational Progress
  Expanded GMP manufacturing capacity to become one of the largest in-house CAR-T manufacturers amongst leading global biopharmaceutical companies Signed partnerships with GE Healthcare Life Sciences China & Thermo Fisher Scientific China to improve cell manufacturing process...
Source: GlobeNewswire
Date: March, 06 2018 09:27
Cellular Biomedicine Group Invited to Present a Keynote Speech at Phar-East Asia Pharma & Biotech Festival
SHANGHAI, China and CUPERTINO, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for de...
Source: GlobeNewswire
Date: March, 01 2018 09:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1619.7019.2019.7018.8524,118
2018-08-1520.2518.9020.2518.8037,547
2018-08-1420.4520.4020.9520.2019,466
2018-08-1320.7020.4020.7020.1013,285
2018-08-1020.8020.3520.8020.2011,438

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-168,49811,97870.9467Short
2018-08-157,81415,35950.8757Short
2018-08-143,4309,87234.7447Cover
2018-08-132,8153,56279.0286Short
2018-08-104,1566,01669.0824Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CBMG.


About Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)

Logo for Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)

Cellular Biomedicine Group, Inc. CBMG is a biomedicine firm engaged in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell technologies, which include, without limitation, i haMPC human adipose derived mesenchymal progenitor cells for treatment of joint disease, ii huMPC human umbilical cord derived mesenchymal progenitor cells , iii TC DC tumor cell specific dendritic cells for treatment of a broad range of cancers and iv MNP human embryo derived motor neuron precursor cells and NP human embryo derived neuronal precursor cells for treatment of central nervous system diseases.

 

 

 

Current Management

  • Wei William Cao / CEO, President
  • Biz Tony Liu / CFO, Secretary
  • Andrew Chan / SVP, Corp. Dev.
  • Sarah Kelly / Director, Comm., Director, Inv. Rel.
  • Jeffrey Auerbach /
  • Terry A. Belmont /
  • David Bolocan /
  • Wei William Cao /
  • Jianping Dai /
  • Gerardus A. Hoogland /
  • Nadir Patel /
  • Keith Wong /

Current Share Structure

  • Market Cap: $321,374,995 - 05/11/2018
  • Issue and Outstanding: 17,003,968 - 02/11/2018

 


Recent Filings from (NASDAQ: CBMG)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 19 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 11 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 09 2018
Pre-effective amendment to an S-3 filing
Filing Type: S-3/AFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 12 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 12 2018

 

 


Daily Technical Chart for (NASDAQ: CBMG)

Daily Technical Chart for (NASDAQ: CBMG)


Stay tuned for daily updates and more on (NASDAQ: CBMG)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CBMG)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CBMG is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CBMG and does not buy, sell, or trade any shares of CBMG. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/